Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Pantaleo G., Janes H., Karuna S., Grant S., Ouedraogo G.L., Allen M., Tomaras G.D., Frahm N., Montefiori D.C., Ferrari G., Ding S., Lee C., Robb M.L., Esteban M., Wagner R., Bart P.A., Rettby N., McElrath M.J., Gilbert P.B., Kublin J.G., Corey L.; NIAID HIV Vaccine Trials Network.
Nov 6, 2019 | Publications